Type 2 Diabetes

PLX204, a novel oral agent for type 2 diabetes, has advanced to Phase 2 clinical trials. PLX204 targets all three PPAR (peroxisome proliferator-activated receptor) receptors—alpha, gamma and delta. In contrast to currently marketed PPAR compounds, PLX204's activity on all three receptors is expected to modulate lipids and cholesterol, as well as lower glucose. This multi-targeted compound, designed to be less potent on each individual receptor and a partial agonist, should have broader therapeutic activity and a wider safety window than current therapies.

Plexxikon is able to design PPAR compounds with activity against any of the three PPAR receptors or any combination of receptors, as well as vary the degree of agonism. The company owns a significant portfolio of novel PPAR compounds with attractive pharmaceutical properties.